The search for the ideal SERM
- 1 June 2002
- journal article
- review article
- Published by Informa Healthcare in Expert Opinion on Pharmacotherapy
- Vol. 3 (6) , 681-691
- https://doi.org/10.1517/14656566.3.6.681
Abstract
Selective oestrogen receptor modulators (SERMs) are compounds that interact with the oestrogen receptor and have tissue-specific effects distinct from those of oestradiol, acting as an oestrogen agonist in some tissues and as an antagonist in others. The development of SERMs that selectively interact with specific receptors, coactivators and corepressors in different organ systems offers the possibility of improving the risk:benefit profile relative to hormone replacement therapy. Tamoxifen is a SERM that acts as an oestrogen antagonist in breast tissue and is currently being used for the treatment and prevention of breast cancer. Tamoxifen also exhibits oestrogen-agonistic properties in the endometrium and increases the risk of endometrial cancer. Oestrogen and another SERM, raloxifene, have been shown to prevent osteoporosis. The effects of oestrogens on cognitive functions are currently being investigated. Recent data reveal the lack of secondary prevention of coronary heart disease with oestrogen. Oestrogen has been used to treat menopausal symptoms, whereas the SERMs have been shown to induce hot flushes. Current research is focused on producing the ideal SERM, which would have benefits over existing SERMs in terms of preventing cancer, cardiovascular disease, osteoporosis and menopausal symptoms, improving cognitive functions, and have a significantly better toxicity profile in terms of endometrial cancer and thromboembolic events.Keywords
This publication has 53 references indexed in Scilit:
- A Clinical Trial of Estrogen-Replacement Therapy after Ischemic StrokeNew England Journal of Medicine, 2001
- Comparative distribution of estrogen receptor-? and -? mRNA in the rat central nervous systemJournal of Comparative Neurology, 1997
- Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancerThe Lancet, 1997
- Prospective study of exogenous hormones and risk of pulmonary embolism in womenThe Lancet, 1996
- Affective Symptoms in Women Attending a Menopause ClinicThe British Journal of Psychiatry, 1994
- Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.Journal of Clinical Investigation, 1994
- Droloxifene, a new antiestrogen: Its role in metastatic breast cancerBreast Cancer Research and Treatment, 1994
- Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidencePreventive Medicine, 1991
- Anti-oestrogenic and anti-tumour properties of prolonged tamoxifen therapy in C3H/OUJ miceEuropean Journal of Cancer and Clinical Oncology, 1990
- Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomataPublished by Elsevier ,1976